Author

C. O'Sullivan

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

PURPOSE EA1181 (ClinicalTrials.gov identifier: NCT04266249) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This report focuses on the secondary end points of pathologic...

N. Tung, Feng-Min Zhao, A. DeMichele et al. · Journal of Clinical Oncology · 1 citation

Review Open access Oct 2026

Treatment of Breast Cancer.

Breast cancer (BC) is the most frequently diagnosed cancer among women and the leading cause of cancer deaths in females globally. In the United States, more than 300,000 new cases of invasive BC are diagnosed annually, and more than 40,000 patients die of metastatic BC. Herein, we discuss the current and evolving mana...

Kathryn J. Ruddy, D. Idossa, Dalliah M. Black et al. · Mayo Clinic proceedings · 0 citations